BD PROJECTS

• PCC

  A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | PharmaTimes BD Opportunity

  2025年8月19日
• Product for Licensing

  【SELL】A Highly Potent, Selective, Tissue-Enriched Oral Pan-KRAS (ON & OFF) Inhibitor for licensing

  2025年8月12日
• Insights

  Approaching $6 Billion! XtalPi Secures Major Out-Licensing Agreement

  2025年8月6日
• Insights

  Failure Against Placebo? Vertex Stumbles in Pursuit of Billion-Dollar Non-Opioid Analgesia Market

  2025年8月6日
• Insights

  Has the mRNA Vaccine Era Collapsed? Kennedy Announces Cancellation of Funding for 22 mRNA Vaccine Projects

  2025年8月6日
• Insights

  Patient Death in Trial Marks Setback for Allogene’s Off-the-shelf CAR-T

  2025年8月5日
• Insights

  CellOrigin’s DLL3 CAR-T Accepted by CDE, China Leads Global DLL3 Therapeutic Development

  2025年8月5日
• Insights

  Q2 Loss of $800 Million, 10% Workforce Reduction, CEO Rejects M&A Deal

  2025年8月5日
• Insights

  World’s First Clinical Improvement! Sun Yat-sen Memorial Hospital Collaborates with Shize Bio to Advance Universal iPSC-Derived Neural Cell Therapy for Spinal Cord Injury

  2025年8月5日
• Small Molecule

  A Potentially Best-in-Class (BIC) Pan-RAS (ON) Inhibitor with Superior PK Profile and Significant Pharmacological Efficacy

  2025年8月4日